NCT05058651: First Line Platinum/Etoposide With or Without Atezolizumab for the Treatment of Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Cancer

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Neuroendocrine tumor (NET)
Recruitment Status: Recruiting
Phase 2|Phase 3
Drug Category: Immunotherapy, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with active symptomatic brain metastasis that require treatment; Patients with leptomeningeal disease; Patients who had prior treatment for metastatic disease EXCEPT one cycle of platinum (carboplatin/cisplatin + etoposide is allowed; Patients with prior treatment of an anti-PD-1, anti-PD-L1, anti-PD-L2, CD137 agonists, anti-CTLA-4 agent, or any other immune checkpoint inhibitors (e.g. Keytruda/pembrolizumab, Tecentriq/atezolizumab)

Comments are closed.

Up ↑